Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Ruxolitinib-Treated Myelofibrosis
NCT04217993Phase 2Completed
- Sponsor
- Zelgen
- Start
- Jan 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Zelgen. Started Jan 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT04217993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217993.